1. Home
  2. GLDD vs GYRE Comparison

GLDD vs GYRE Comparison

Compare GLDD & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Great Lakes Dredge & Dock Corporation

GLDD

Great Lakes Dredge & Dock Corporation

HOLD

Current Price

$13.37

Market Cap

814.6M

Sector

Industrials

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$7.28

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GLDD
GYRE
Founded
1890
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
814.6M
755.7M
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
GLDD
GYRE
Price
$13.37
$7.28
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
400.7K
91.0K
Earning Date
11-04-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
36.27
N/A
EPS
1.19
0.04
Revenue
$834,599,000.00
$107,265,000.00
Revenue This Year
$12.71
$11.59
Revenue Next Year
$4.77
$26.31
P/E Ratio
$11.22
$185.48
Revenue Growth
12.53
2.13
52 Week Low
$7.51
$6.11
52 Week High
$14.02
$14.42

Technical Indicators

Market Signals
Indicator
GLDD
GYRE
Relative Strength Index (RSI) 55.64 42.05
Support Level $13.28 $7.05
Resistance Level $13.60 $7.39
Average True Range (ATR) 0.36 0.35
MACD -0.06 -0.06
Stochastic Oscillator 43.10 22.61

Price Performance

Historical Comparison
GLDD
GYRE

About GLDD Great Lakes Dredge & Dock Corporation

Great Lakes Dredge & Dock Corp is a provider of dredging services in the United States. The Company is also fully engaged in expanding its core business into the offshore energy industry. Dredging involves the enhancement or preservation of the navigability of waterways or the protection of shorelines through the removal or replenishment of soil, sand, or rock. Company work generally is to performed in coastal waterways and deep water ports. Its project portfolio includes Coastal Restoration, Coastal Protection, Ports and Harbors, International, and Inland Dredging.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: